Or ingest cannabis however you choose to imbibe.
A recent study (non-peer reviewed, presented at the American College of Gatroenterology 2020 Annual Scientific Meeting) finds that the “anti-inflammatory effects of cannabis may be leading to reduced prevalence of steatohepatitis”
WTF is steatohepatitis (you may well ask)?
Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in the liver. (Wikipedia.)
Many fat people have non-alcoholic fatty liver disease (NAFLD). When inflammation occurs (steatohepatitis), there can be damage to the liver, which can progress to or contribute to cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).
Looking at a bunch (879,952 – I think that qualifies as a “bunch”) of discharge records of fat (obese) adults in 2016, the researchers found a prevalence of steatosis (fatty liver); steatohepatitis, cirrhosis and hepatocellular carcinoma.
When the researchers compared the disease stages of cannabis users and non-users, they found steatohepatitis was significantly less common with cannabis users.
Cannabis use was not associated to a reduction in prevalence of NAFLD, cirrhosis or liver cancer.
While these results are interesting, they are far from conclusive and a lot more research is needed because there are a lot of fundamental problems with this initial study – like nobody knows how much cannabis needs to be ingested to have an effect – now and then or wake and bake? And do you have to smoke it or can you do edibles? Is it an effect of CBD or THC – or something else?
This is very interesting to me because many fat-related health problems are supposed to be due to inflammation of one kind or another. If cannabis has an anti-inflammatory effect, you have to start wondering what other kinds of fat-related inflammation can be reduced or stopped, and what kind of an effect would that have on the health of fat people.
Come on science – time to start getting fatties high and get some answers!